Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 546 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Normal Saline IV Administration Clear all

Conditions: Chorioamnionitis
Interventions: saline, ampicillin gentamicin, ampicillin gentamicin clindamycin; Drug
Lead sponsor: United States Naval Medical Center, Portsmouth; Federal
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Portsmouth, Virginia

Conditions: Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions: 18-NaF PET, DCE-MRI, 18-FDG PET/CT; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Emphysema in Alpha-1 PI Deficiency
Interventions: Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP; Biological · Other
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 10
States / cities: Phoenix, Arizona • Gainesville, Florida • Leesburg, Florida + 7 more

Conditions: Subarachnoid Hemorrhage, Stroke
Interventions: IV acetaminophen, Oral acetaminophen, Oral placebo, IV placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19
Interventions: IVIG (intravenous immunoglobulin), IVIG Placebo, Coordinated Care, Usual Care; Drug · Behavioral
Lead sponsor: Kanecia Obie Zimmerman; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cerebrovascular Accident
Interventions: Magnesium Sulfate, Normal Saline; Drug
Lead sponsor: Jeffrey L. Saver; Other
Eligibility: 40 Years to 95 Years
Enrollment: 1,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder
Interventions: Ketamine, Saline, Magnetic Resonance Imaging (MRI); Drug · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypovolemia
Interventions: Kedbumin 25%, Normal Saline Solution; Drug
Lead sponsor: Kedrion S.p.A.; Industry
Eligibility: Up to 12 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 2
States / cities: Louisville, Kentucky • Milwaukee, Wisconsin

Conditions: Atopic Asthma
Interventions: abatacept, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Multiple Myeloma
Interventions: Allopurinol, Carmustine, Etoposide, Cytarabine, Melphalan; Drug
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Localized Prostate Cancer
Interventions: Aquablation Therapy, Radical Prostatectomy; Device · Procedure
Lead sponsor: PROCEPT BioRobotics; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 26
States / cities: Chandler, Arizona • Mesa, Arizona • Los Angeles, California + 22 more

Conditions: Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions: Abatacept, Normal Saline, D5W; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 6 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 27
States / cities: Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more

Conditions: Subarachnoid Hemorrhage, Acute Kidney Injury
Interventions: Sodium chloride /sodium acetate (16.4%), Sodium chloride (23.4%), PlasmaLyte; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Alcohol Use Disorder
Interventions: Intravenous Alcohol; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Covid19
Interventions: VIR-7831 (sotrovimab), Placebo; Biological · Drug
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,057 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 63
States / cities: Anniston, Alabama • Cullman, Alabama • Mesa, Arizona + 49 more

Conditions: Abdominal Wall Hernia, Pancreatic Diseases, Bowel Disease, Gastric Disease
Interventions: Acetaminophen Injectable Product, Sodium Chloride 0.9%, Intravenous; Drug
Lead sponsor: Kathirvel Subramaniam; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Glomerular Filtration Rate, Acute Kidney Injury
Interventions: Below target dose MP-3180, At target dose MP-3180, 2 times above target dose MP-3180, 4 times above target dose MP-3180, ORFM prototype, Iohexol comparator; Drug · Device · Other
Lead sponsor: MediBeacon; Industry
Eligibility: 22 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Crohn Disease (CD)
Interventions: DB-3Q, Placebo; Biological · Other
Lead sponsor: Direct Biologics, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Gastrointestinal Dysmotility
Interventions: Saline Solution for Injection, Ipamorelin; Drug
Lead sponsor: Helsinn Therapeutics (U.S.), Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 45
States / cities: Florence, Alabama • Sheffield, Alabama • Fountain Valley, California + 42 more

Conditions: Graft Rejection
Interventions: Placebo, C1 Esterase Inhibitor (Human); Biological
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 1 more

Conditions: Analgesia, Obstetrical, Coagulation Defect; Postpartum, Nonsteroidals (NSAIDs)Toxicity, Postpartum Hemorrhage, Postoperative Pain, Ketorolac Adverse Reaction, Blood Loss, Postoperative
Interventions: Ketorolac Tromethamine 30 MG/ML, Placebos; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Melanoma
Interventions: Intismeran autogene, Pembrolizumab, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,089 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 34
States / cities: Springdale, Arkansas • Los Angeles, California • San Francisco, California + 27 more

Conditions: Coronary Artery Disease
Interventions: Methylnaltrexone, Placebo, Morphine, Ticagrelor; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Venous Thrombosis
Interventions: MK-2060, Placebo; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Miami, Florida • Knoxville, Tennessee

Search by objective public record fields.

Treatment of Chorioamnionitis After Delivery

Imaging in MGUS, SMM and MM

Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

Clinical, Pharmacological and Molecular Effects of IV and Oral Acetaminophen in Adults With aSAH

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial

Ketamine in the Treatment of Depression

Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients

The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

WATER IV Prostate Cancer

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

A Low ChloridE hyperTonic Solution for Brain Edema

Motivation for IV Alcohol Self-Administration in Humans

VIR-7831 for the Early Treatment of COVID-19 in Outpatients

IV Acetaminophen for Post-Operative Pain Management in Enhanced Recovery After Surgery (ERAS) Population

Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy Volunteers

DB-3Q for the Treatment of Medically Refractory Crohn's Disease

Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function

A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

IV Ketorolac on Platelet Function Post-Cesarean Delivery

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine

A Study of MK-2060 in Healthy Participants (MK-2060-016)